Anksiyolitik ve Sedatif Hipnotikler
Özet
Anksiyolitik, sedatif ve hipnotik ilaçlar, temel olarak beyindeki ana inhibitör nörotransmitter olan Gama Amino Bütirik Asit (GABA) sistemi üzerinden veya adrenerjik, serotonerjik ve melatoninerjik yolaklar aracılığıyla etki göstererek kaygı bozuklukları ve uykusuzluk tedavisinde yaygın olarak kullanılan ajanlardır. Bu ilaç gruplarının en sık reçete edilenleri arasında yer alan benzodiazepinler; kaygı giderici, kas gevşetici ve antikonvulzan etkilere sahip olmakla birlikte uyuşukluk, amnezi, paradoksik taşkınlık gibi belirgin yan etkilere yol açabilir; uzun süreli kullanımlarında ise tolerans, yoksunluk semptomları ve bağımlılık riski taşırlar. Benzodiazepin dışı birer alternatif olan Z-ilaçları ve melatonin reseptör agonistleri daha çok hipnotik etkileriyle uyku bozukluklarında tercih edilirken; buspiron bağımlılık riski olmaksızın yaygın anksiyete bozukluğunda, beta blokerler ise anksiyetenin otonomik hiperaktivitesini baskılamada kullanılır. Birinci jenerasyon antihistaminikler sedatif özellikleri nedeniyle sakinleştirici olarak, kalsiyum kanallarına bağlanan GABA analogları (pregabalin ve gabapentin) ise özellikle dirençli kaygı durumlarında endikasyon dışı tedavi olarak öne çıkmaktadır. Güncel klinik araştırmalar, geleneksel sistemlerin ötesine geçerek glutamat, nöropeptit, nörosteroid yolakları ve ketamin gibi yeni farmakoterapiler üzerine yoğunlaşmaktadır.
Anxiolytic, sedative, and hypnotic drugs are agents widely used in the treatment of anxiety disorders and insomnia, primarily acting through the Gamma-Aminobutyric Acid (GABA) system, which is the main inhibitory neurotransmitter in the brain, or via adrenergic, serotonergic, and melatoninergic pathways. Benzodiazepines, which are among the most frequently prescribed of these drug groups, possess anxiolytic, muscle relaxant, and anticonvulsant effects; however, they can lead to prominent side effects such as drowsiness, amnesia, and paradoxical disinhibition, and they carry risks of tolerance, withdrawal symptoms, and dependence during long-term use. While Z-drugs and melatonin receptor agonists, which are non-benzodiazepine alternatives, are preferred in sleep disorders chiefly for their hypnotic effects; buspirone is used in generalized anxiety disorder without the risk of dependence, and beta-blockers are utilized to suppress the autonomic hyperactivity of anxiety. First-generation antihistamines are employed as sedatives due to their calming properties, whereas GABA analogs (pregabalin and gabapentin) that bind to calcium channels stand out as off-label treatments, particularly in refractory anxiety conditions. Current clinical research shifts beyond traditional systems, focusing on novel pharmacotherapies including glutamate, neuropeptide, and neurosteroid pathways, as well as ketamine.
Referanslar
Zwanzger P, Singewald N, Bandelow B. [Pharmacotherapy of anxiety disorders-Guideline-conform treatment and new developments]. Der Nervenarzt. Nervenarzt; 2021;92(5): 433–440. doi:10.1007/S00115-020-01051-3
STAHL SM. Stahl’ın Temel Psikofarmakolojisi, Sinirbilimsel Temeli ve Pratik Uygulaması.. 4.Baskı. ALKIN T (ed.) İstanbul: İstanbul Tıp Kitapevi; 2015. 1–608 p.
SADOCK BJ. Kaplan Sadock Psikiyatri.. 11th ed. BOZKURT A (ed.) İstanbul: Güneş Tıp Kitapevi; 2016. 910–1060 p.
Öztürk O, Uluşahin A. Mental Health and Disorders [Ruh Sağlığı ve Bozuklukları]. Nobel Tıp Kitabevleri. Nobel Tıp Kitabevleri; 2018; 1–788. https://nobeltip.com/product/224/ruh-sagligi-ve-bozukluklari
Seldenrijk A, Vis R, Henstra M, et al. [Systematic review of the side effects of benzodiazepines]. Nederlands tijdschrift voor geneeskunde. Ned Tijdschr Geneeskd; 2017;161(43). https://pubmed.ncbi.nlm.nih.gov/29076441/
Karcıoğlı Ö. Benzodiazepin Zehirlenmeleri. Acilde Klinik Toksikoloji. 2009. p. 193–212. https://www.researchgate.net/publication/294086853_Benzodiazepin_Zehirlenmeleri/citation/download
Joint Formulary Committee. British national formulary. 67, March-September 2014. Pharmaceutical Press,; 2014;
Soyka M. Treatment of Benzodiazepine Dependence. The New England journal of medicine. N Engl J Med; 2017;376(12): 1147–1157. doi:10.1056/NEJMRA1611832
Markota M, Rummans TA, Bostwick JM, et al. Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies. Mayo Clinic proceedings. Mayo Clin Proc; 2016;91(11): 1632–1639. doi:10.1016/J.MAYOCP.2016.07.024
Picton JD, Brackett Marino A, Lovin Nealy K. Benzodiazepine use and cognitive decline in the elderly. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. Am J Health Syst Pharm; 2018;75(1): e6–e12. doi:10.2146/AJHP160381
Shyken JM, Babbar S, Babbar S, et al. Benzodiazepines in Pregnancy. Clinical obstetrics and gynecology. Clin Obstet Gynecol; 2019;62(1): 156–167. doi:10.1097/GRF.0000000000000417
Stahl SM, Grady MM, Munter N. Stahl’ın temel psikofarmakolojisi : reçete kılavuzu.. 5th ed. Uzbay IT (ed.) İstanbul Tıp Kitapevleri ; 2017. 871 p.
Dokkedal-Silva V, Berro LF, Galduróz JCF, et al. Clonazepam: Indications, Side Effects, and Potential for Nonmedical Use. Harvard review of psychiatry. Harv Rev Psychiatry; 2019;27(5): 279–289. doi:10.1097/HRP.0000000000000227
Jiang S, Brownell KC, Kamper JE, et al. Clonazepam for Catatonia Incompletely Responsive to Lorazepam. Journal of the Academy of Consultation-Liaison Psychiatry. Elsevier; 2021;62(1): 97–101. doi:10.1016/J.PSYM.2020.09.009
Amore M, D’Andrea M, Fagiolini A. Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review. Frontiers in psychiatry. Front Psychiatry; 2021;12. doi:10.3389/FPSYT.2021.628965
Pelzer ACM, van der Heijden FMMA, den Boer E. Systematic review of catatonia treatment. Neuropsychiatric disease and treatment. Neuropsychiatr Dis Treat; 2018;14: 317–326. doi:10.2147/NDT.S147897
Smith S, Ketheesan S, Touma E, et al. Lorazepam challenge test for catatonia. Emergency medicine Australasia : EMA. Emerg Med Australas; 2021;33(4): 763–764. doi:10.1111/1742-6723.13780
Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. JAMA. JAMA; 2017;318(11): 1047–1056. doi:10.1001/JAMA.2017.11468
Ait-Daoud N, Hamby AS, Sharma S, et al. A Review of Alprazolam Use, Misuse, and Withdrawal. Journal of addiction medicine. J Addict Med; 2018;12(1): 4–10. doi:10.1097/ADM.0000000000000350
Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in Psychiatry. Frontiers Media SA; 2020;11: 595584. doi:10.3389/FPSYT.2020.595584
Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine. American Academy of Sleep Medicine; 2017;13(2): 307. doi:10.5664/JCSM.6470
Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of psychopharmacology (Oxford, England). J Psychopharmacol; 2010;24(11): 1601–1612. doi:10.1177/0269881109106927
Louzada LL, Machado F v., Nóbrega OT, et al. Zopiclone to treat insomnia in older adults: A systematic review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. Eur Neuropsychopharmacol; 2021;50: 75–92. doi:10.1016/J.EURONEURO.2021.04.013
Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clinical therapeutics. Clin Ther; 2006;28(4): 491–516. doi:10.1016/J.CLINTHERA.2006.04.014
Rösner S, Englbrecht C, Wehrle R, et al. Eszopiclone for insomnia. The Cochrane database of systematic reviews. Cochrane Database Syst Rev; 2018;10(10). doi:10.1002/14651858.CD010703.PUB2
Xiang T, Cai Y, Hong Z, et al. Efficacy and safety of Zolpidem in the treatment of insomnia disorder for one month: a meta-analysis of a randomized controlled trial. Sleep Medicine. Elsevier; 2021;87: 250–256. doi:10.1016/J.SLEEP.2021.09.005
Bomalaski MN, Claflin ES, Townsend W, et al. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. JAMA neurology. JAMA Neurol; 2017;74(9): 1130–1139. doi:10.1001/JAMANEUROL.2017.1133
Chen LE, Zhao AD, Zhang QJ, et al. Investigation of the usefulness of zaleplon at two doses to induce afternoon-sleep under noise interference and its effects on psychomotor performance and vestibular function. Military Medical Research. Mil Med Res; 2016;3(1). doi:10.1186/S40779-016-0075-4
Goldschmied JR, Sengupta A, Sharma A, et al. Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression. Psychopharmacology Bulletin. MedWorks Media Inc.; 2021;51(3): 50. /pmc/articles/PMC8374930/
Oliver E, Mayor Jr F, D’Ocon P. Beta-blockers: Historical Perspective and Mechanisms of Action. Revista espanola de cardiologia (English ed.). Rev Esp Cardiol (Engl Ed); 2019;72(10): 853–862. doi:10.1016/J.REC.2019.04.006
Steenen SA, van Wijk AJ, van der Heijden GJMG, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology (Oxford, England). SAGE Publications; 2016;30(2): 128. doi:10.1177/0269881115612236
Argolo FC, Cavalcanti-Ribeiro P, Netto LR, et al. Prevention of posttraumatic stress disorder with propranolol: A meta-analytic review. Journal of Psychosomatic Research. Elsevier; 2015;79(2): 89–93. doi:10.1016/J.JPSYCHORES.2015.04.006
Liu X, Lou X, Cheng X, et al. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. Drug Design, Development and Therapy. Dove Press; 2017;11: 305. doi:10.2147/DDDT.S124497
Armstrong C, Kapolowicz MR. A Preliminary Investigation on the Effects of Atenolol for Treating Symptoms of Anxiety. Military Medicine. Oxford Academic; 2020;185(11–12): e1954–e1960. doi:10.1093/MILMED/USAA170
Naguy A. Clonidine Use in Psychiatry: Panacea or Panache? Pharmacology. Karger Publishers; 2016;98(1–2): 87–92. doi:10.1159/000446441
Hudson N, Burghart S, Reynoldson J, et al. Evaluation of low dose prazosin for PTSD-associated nightmares in children and adolescents. The Mental Health Clinician. College of Psychiatric and Neurologic Pharmacists (CPNP); 2021;11(2): 45. doi:10.9740/MHC.2021.03.045
Reist C, Streja E, Tang CC, et al. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectrums. Cambridge University Press; 2021;26(4): 338–344. doi:10.1017/S1092852920001121
Breen A, Blankley K, Fine J. The efficacy of prazosin for the treatment of posttraumatic stress disorder nightmares in U.S. military veterans. Journal of the American Association of Nurse Practitioners. Blackwell Publishing Ltd; 2017;29(2): 65–69. doi:10.1002/2327-6924.12432
Howland RH. Buspirone: Back to the future. Journal of Psychosocial Nursing and Mental Health Services. Slack Incorporated; 2015;53(11): 21–24. doi:10.3928/02793695-20151022-01
Wilson TK, Tripp J. Buspirone. xPharm: The Comprehensive Pharmacology Reference. StatPearls Publishing; 2022; 1–5. doi:10.1016/B978-008055232-3.61355-8
Kowacs DP, Folchini CM, de Moura Vieira KR, et al. Use of Buspirone in the Treatment of Nonpharmacological Bruxism: About 4 Cases. Clinical neuropharmacology. NLM (Medline); 2021;44(6): 247–249. doi:10.1097/WNF.0000000000000486
Loane C, Politis M. Buspirone: What is it all about? Brain Research. Elsevier; 2012;1461: 111–118. doi:10.1016/J.BRAINRES.2012.04.032
Cruz MRS, Hidalgo PC, Lee MS, et al. Buspirone for the treatment of dementia with behavioral disturbance. International Psychogeriatrics. Cambridge University Press; 2017;29(5): 859–862. doi:10.1017/S1041610216002441
Mahmood I, Sahajwalla C. Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug. Clinical Pharmacokinetics 1999 36:4. Springer; 2012;36(4): 277–287. doi:10.2165/00003088-199936040-00003
Strawn JR, Mills JA, Cornwall GJ, et al. Buspirone in Children and Adolescents with Anxiety: A Review and Bayesian Analysis of Abandoned Randomized Controlled Trials. Journal of Child and Adolescent Psychopharmacology. Mary Ann Liebert, Inc.; 2018;28(1): 2. doi:10.1089/CAP.2017.0060
Church MK. Allergy, histamine and antihistamines. Handbook of Experimental Pharmacology. Springer New York LLC; 2017;241: 321–331. doi:10.1007/164_2016_85
Parsons ME, Ganellin CR. Histamine and its receptors. British Journal of Pharmacology. John Wiley & Sons, Ltd; 2006;147(S1): S127–S135. doi:10.1038/SJ.BJP.0706440
Chu DK, Oykhman P, Sussman GL. How to use antihistamines. CMAJ. Canadian Medical Association; 2021;193(14): E478–E479. doi:10.1503/CMAJ.201959/TAB-RELATED-CONTENT
Hydroxyzine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2017; https://www.ncbi.nlm.nih.gov/books/NBK548128/
Ghanizadeh A, Zare S. A preliminary randomised double-blind placebo-controlled clinical trial of hydroxyzine for treating sleep bruxism in children. Journal of Oral Rehabilitation. John Wiley & Sons, Ltd; 2013;40(6): 413–417. doi:10.1111/JOOR.12049
Mahr F, Billman M, Essayli JH, et al. Selective Serotonin Reuptake Inhibitors and Hydroxyzine in the Treatment of Avoidant/Restrictive Food Intake Disorder in Children and Adolescents: Rationale and Evidence. https://home.liebertpub.com/cap. Mary Ann Liebert, Inc., publishers 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA ; 2022;32(2): 117–121. doi:10.1089/CAP.2021.0038
Wong HCG. Long-term use of diphenhydramine. CMAJ : Canadian Medical Association Journal. Canadian Medical Association; 2015;187(14): 1078. doi:10.1503/CMAJ.1150066
Badr B, Naguy A. Cyproheptadine: a psychopharmacological treasure trove? CNS Spectrums. Cambridge University Press; 2021; 1–3. doi:10.1017/S1092852921000250
Simon L v., Keenaghan M. Serotonin Syndrome. Pain Medicine: An Essential Review. StatPearls Publishing; 2022;11(9): 201–202. https://www.ncbi.nlm.nih.gov/books/NBK482377/
Prakash S, Rathore C, Rana K, et al. Chronic serotonin syndrome: A retrospective study. World Journal of Psychiatry. Baishideng Publishing Group Inc; 2021;11(4): 124. doi:10.5498/WJP.V11.I4.124
Abdel-Hamid IA, Elsaied MA, Mostafa T. The drug treatment of delayed ejaculation. Translational Andrology and Urology. AME Publications; 2016;5(4): 576. doi:10.21037/TAU.2016.05.05
Allison M, Hale C. A Phase I Study of the Pharmacokinetics and Pharmacodynamics of Intranasal Doxylamine in Subjects with Chronic Intermittent Sleep Impairment. Drugs in R and D. Springer International Publishing; 2018;18(2): 129–136. doi:10.1007/S40268-018-0232-1/FIGURES/4
Khorasani F, Aryan H, Sobhi A, et al. A systematic review of the efficacy of alternative medicine in the treatment of nausea and vomiting of pregnancy. https://doi.org/10.1080/01443615.2019.1587392. Taylor & Francis; 2019;40(1): 10–19. doi:10.1080/01443615.2019.1587392
Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends in pharmacological sciences. Trends Pharmacol Sci; 2007;28(2): 75–82. doi:10.1016/J.TIPS.2006.12.006
Sills GJ. The mechanisms of action of gabapentin and pregabalin. Current Opinion in Pharmacology. Elsevier; 2006;6(1): 108–113. doi:10.1016/J.COPH.2005.11.003
Cross AL, Viswanath O, Sherman A l. Pregabalin. The Essence of Analgesia and Analgesics. StatPearls Publishing; 2022; 298–301. doi:10.1017/CBO9780511841378.072
Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Internal Medicine. American Medical Association; 2019;179(5): 695–701. doi:10.1001/JAMAINTERNMED.2019.0086
Houghton KT, Forrest A, Awad A, et al. Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. BMJ Open. BMJ Publishing Group; 2017;7(3): 13433. doi:10.1136/BMJOPEN-2016-013433
Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: An updated systematic review and meta-analysis. International Clinical Psychopharmacology. Lippincott Williams and Wilkins; 2017;32(1): 49–55. doi:10.1097/YIC.0000000000000147
Olivares JM, Álvarez E, Carrasco JL, et al. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. International Clinical Psychopharmacology. Lippincott Williams and Wilkins; 2015;30(5): 265–271. doi:10.1097/YIC.0000000000000087
Baldwin DS, den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. Journal of Psychopharmacology. SAGE Publications Ltd; 2015;29(10): 1047–1060. doi:10.1177/0269881115598411
Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. Journal of clinical psychopharmacology. J Clin Psychopharmacol; 2000;20(4): 467–471. doi:10.1097/00004714-200008000-00011
Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of clinical psychopharmacology. J Clin Psychopharmacol; 1999;19(4): 341–348. doi:10.1097/00004714-199908000-00010
Lavigne JE, Heckler C, Mathews JL, et al. A Randomized, Controlled, Double-Blinded Clinical Trial of Gabapentin 300mg versus 900mg versus Placebo for Anxiety Symptoms in Breast Cancer Survivors. Breast cancer research and treatment. NIH Public Access; 2012;136(2): 479. doi:10.1007/S10549-012-2251-X
Önder E, Tural Ü, Gökbakan M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder? European Archives of Psychiatry and Clinical Neuroscience 2008 258:6. Springer; 2008;258(6): 319–323. doi:10.1007/S00406-007-0798-Z
Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. Journal of clinical pharmacology. J Clin Pharmacol; 2003;43(3): 277–283. doi:10.1177/0091270003251119
Bockbrader HN, Wesche D, Miller R, et al. A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin. Clinical Pharmacokinetics 2010 49:10. Springer; 2012;49(10): 661–669. doi:10.2165/11536200-000000000-00000
Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. European Neuropsychopharmacology. Elsevier; 2017;27(12): 1185–1215. doi:10.1016/J.EURONEURO.2017.08.430
Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacology, biochemistry, and behavior. Pharmacol Biochem Behav; 2012;100(3): 560–565. doi:10.1016/J.PBB.2011.10.023
[On the history of barbiturates] - PubMed. [Online] https://pubmed.ncbi.nlm.nih.gov/27086450/
López-Muñoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatric Disease and Treatment. Dove Press; 2005;1(4): 329. /pmc/articles/PMC2424120/
’Özçelik F ’Erdem. M ’Bolu, A ’Gülsün, M. Melatonin : Genel Özellikleri ve Psikiyatrik Bozukluklardaki Rolü. Psikiyatride Güncel Yaklaşımlar-Current Approaches in Psychiatry. 2013;5(2): 179–2013.
Xie Z, Chen F, Li WA, et al. A review of sleep disorders and melatonin. https://doi.org/10.1080/01616412.2017.1315864. Taylor & Francis; 2017;39(6): 559–565. doi:10.1080/01616412.2017.1315864
Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Medicine. Elsevier; 2014;15(4): 385–392. doi:10.1016/J.SLEEP.2013.11.788
Ramelteon. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2018; https://www.ncbi.nlm.nih.gov/books/NBK548437/
Low TL, Choo FN, Tan SM. The efficacy of melatonin and melatonin agonists in insomnia – An umbrella review. Journal of Psychiatric Research. Pergamon; 2020;121: 10–23. doi:10.1016/J.JPSYCHIRES.2019.10.022
Buoli M, Grassi S, Serati M, et al. Agomelatine for the treatment of generalized anxiety disorder. Expert opinion on pharmacotherapy. Expert Opin Pharmacother; 2017;18(13): 1373–1379. doi:10.1080/14656566.2017.1359257
Macisaac SE, Carvalho AF, Cha DS, et al. The mechanism, efficacy, and tolerability profile of agomelatine. https://doi.org/10.1517/14656566.2014.862233. Taylor & Francis; 2014;15(2): 259–274. doi:10.1517/14656566.2014.862233
Nishimon S, Nishimon M, Nishino S. Tasimelteon for treating non-24-h sleep-wake rhythm disorder. https://doi.org/10.1080/14656566.2019.1603293. Taylor & Francis; 2019;20(9): 1065–1073. doi:10.1080/14656566.2019.1603293
Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. Neuropsychopharmacology; 2008;33(7): 1603–1610. doi:10.1038/SJ.NPP.1301531
Kent JM, Daly E, Kezic I, et al. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Progress in neuro-psychopharmacology & biological psychiatry. Prog Neuropsychopharmacol Biol Psychiatry; 2016;67: 66–73. doi:10.1016/J.PNPBP.2016.01.009
Krystal JH, Mathew SJ, Dsouza DC, et al. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS drugs. CNS Drugs; 2010;24(8): 669–693. doi:10.2165/11533230-000000000-00000
Engin E, Treit D, Dickson CT. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience. Neuroscience; 2009;161(2): 359–369. doi:10.1016/J.NEUROSCIENCE.2009.03.038
Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. The Journal of clinical psychiatry. J Clin Psychiatry; 2020;81(4). doi:10.4088/JCP.19R12889
Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular psychiatry. Mol Psychiatry; 2020;25(7): 1592–1603. doi:10.1038/S41380-018-0256-5
Glue P, Medlicott NJ, Harland S, et al. Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of psychopharmacology (Oxford, England). J Psychopharmacol; 2017;31(10): 1302–1305. doi:10.1177/0269881117705089
Abdallah CG, Coplan JD, Jackowski A, et al. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. Eur Neuropsychopharmacol; 2013;23(4): 276–284. doi:10.1016/J.EURONEURO.2012.05.009
Sugiyama A, Saitoh A, Iwai T, et al. Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines. Neuropharmacology. Neuropharmacology; 2012;62(8): 2489–2498. doi:10.1016/J.NEUROPHARM.2012.02.012
Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Journal of Clinical Psychopharmacology. 2009;29(1): 51–55. doi:10.1097/JCP.0b013e318192e9a4
Myers KM, Carlezon WA, Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. Neuropsychopharmacology; 2011;36(1): 274–293. doi:10.1038/NPP.2010.88
Bailey JE, Papadopoulos A, Lingford-Hughes A, et al. D-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology. Psychopharmacology (Berl); 2007;193(4): 579–585. doi:10.1007/S00213-007-0817-9
Hoffmann E, Nomikos GG, Kaul I, et al. SAGE-217, A Novel GABA A Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies. Clinical pharmacokinetics. Clin Pharmacokinet; 2020;59(1): 111–120. doi:10.1007/S40262-019-00801-0
Wise T, Patrick F, Meyer N, et al. Cholinergic Modulation of Disorder-Relevant Neural Circuits in Generalized Anxiety Disorder. Biological psychiatry. Biol Psychiatry; 2020;87(10): 908–915. doi:10.1016/J.BIOPSYCH.2019.12.013
Simen A, Whitlock M, Qiu R, et al. An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder. Journal of clinical psychopharmacology. J Clin Psychopharmacol; 2019;39(1): 20–27. doi:10.1097/JCP.0000000000000997
Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. Complementary therapies in clinical practice. Complement Ther Clin Pract; 2018;33: 107–117. doi:10.1016/J.CTCP.2018.09.003
Rana T, Behl T, Sehgal A, et al. Exploring the role of neuropeptides in depression and anxiety. Progress in neuro-psychopharmacology & biological psychiatry. Prog Neuropsychopharmacol Biol Psychiatry; 2022;114. doi:10.1016/J.PNPBP.2021.110478
Yoon S, Kim YK. The Role of the Oxytocin System in Anxiety Disorders. Advances in experimental medicine and biology. Adv Exp Med Biol; 2020;1191: 103–120. doi:10.1007/978-981-32-9705-0_7
Acheson DT, Feifel D, Kamenski M, et al. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. Depression and anxiety. Depress Anxiety; 2015;32(6): 400–407. doi:10.1002/DA.22362
Michelson D, Hargreaves R, Alexander R, et al. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. The international journal of neuropsychopharmacology. Int J Neuropsychopharmacol; 2013;16(1): 1–11. doi:10.1017/S1461145712000065
Iftikhar K, Siddiq A, Baig SG, et al. Substance P: A neuropeptide involved in the psychopathology of anxiety disorders. Neuropeptides. Neuropeptides; 2020;79. doi:10.1016/J.NPEP.2019.101993
Sayed S, van Dam NT, Horn SR, et al. A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. The international journal of neuropsychopharmacology. Int J Neuropsychopharmacol; 2018;21(1): 3–11. doi:10.1093/IJNP/PYX109
Mathé AA, Michaneck M, Berg E, et al. A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. The international journal of neuropsychopharmacology. Int J Neuropsychopharmacol; 2020;23(12): 783–790. doi:10.1093/IJNP/PYAA054
Griebel G, Beeské S, Stahl SM. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. The Journal of clinical psychiatry. J Clin Psychiatry; 2012;73(11): 1403–1411. doi:10.4088/JCP.12M07804
Ballaz SJ, Bourin M, Akil H, et al. Blockade of the cholecystokinin CCK-2 receptor prevents the normalization of anxiety levels in the rat. Progress in neuro-psychopharmacology & biological psychiatry. Prog Neuropsychopharmacol Biol Psychiatry; 2020;96. doi:10.1016/J.PNPBP.2019.109761
Zwanzger P, Domschke K, Bradwejn J. Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depression and anxiety. Depress Anxiety; 2012;29(9): 762–774. doi:10.1002/DA.21919
Eser D, Baghai T, Schule C, et al. Neuroactive steroids as endogenous modulators of anxiety. Current pharmaceutical design. Curr Pharm Des; 2008;14(33): 3525–3533. doi:10.2174/138161208786848838
Lenze EJ, Hershey T, Newcomer JW, et al. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone. International journal of geriatric psychiatry. NIH Public Access; 2014;29(9): 962. doi:10.1002/GPS.4085
Liebowitz MR, Hanover R, Draine A, et al. Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder. Depression and anxiety. Depress Anxiety; 2016;33(12): 1081–1089. doi:10.1002/DA.22546
Lin J, Su Y, Wang C, et al. Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: A multicenter, randomized, parallel-controlled, open-label study. Journal of psychiatric research. J Psychiatr Res; 2018;99: 104–110. doi:10.1016/J.JPSYCHIRES.2018.01.020
Kaur Gill A, Bansal Y, Bhandari R, et al. Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties. Drugs of today (Barcelona, Spain : 1998). Drugs Today (Barc); 2019;55(7): 423–437. doi:10.1358/DOT.2019.55.7.2958474
Yee A, Ng CG, Seng LH. Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study. Current drug targets. Curr Drug Targets; 2018;19(12): 1412–1423. doi:10.2174/1389450118666171117131151
Schneier FR, Moskow DM, Choo TH, et al. A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder. Depression and anxiety. Depress Anxiety; 2017;34(12): 1085–1095. doi:10.1002/DA.22693
Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. Asian Journal of Psychiatry. Elsevier Science B.V.; 2017;26: 115–122. doi:10.1016/J.AJP.2017.01.016
